SCIENTIFIC publications

/cun/en/investigacion/publicaciones-cientificas/areaMain/02
  • Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression

    Segovia C (1,2,3), San José-Enériz E (2,4), Munera-Maravilla E (1,3), Martínez-Fernández M (1,2,3,5), Garate L (2,6), Miranda E (2,4), Vilas-Zornoza A (2,4), Lodewijk I (1), Rubio C (2,3), Segrelles C (1,2), Valcárcel LV (2,4,7), Rabal O (8), Casares N (9), Bernardini A (1,2), Suarez-Cabrera C (3), López-Calderón FF 1,2,3, Fortes P (10), Casado JA (11), Dueñas M (1,2,3), Villacampa F (2,3), Lasarte JJ (9), Guerrero-Ramos F (3,12), de Velasco G (3,13), Oyarzabal J (8), Castellano D (1,2,13), Agirre X (14,15), Prósper F (16,17,18), Paramio JM (19,20,21).

    (1) Molecular Oncology Unit CIEMAT, Madrid, Spain.
    (2) Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain.
    (3) Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid, Spain.
    (4) Hemato-oncology Program, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, Pamplona, Spain.
    (5) Mobile Genomes and Disease Laboratory CIMUS, Universidad de Santiago de Compostela, La Coruña, Spain.
    (6) Hematology and Cell Therapy Department, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain.
    (7) TECNUN, University of Navarra, San Sebastián, Spain.
    (8) Small Molecule Discovery Platform, Molecular Therapeutics Program, Centro de Investigación Médica Aplicada, Universidad de Navarra, Pamplona, Spain.
    (9) Immunology and Immunotherapy Program, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, Pamplona, Spain.
    (10) Gene Therapy and Regulation of Gene Expression Program, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, Pamplona, Spain.
    (11) Division of Hematopoietic Innovative Therapies (CIEMAT), Centro de Investigación Biomédica en Red de Enfermedades Raras and Advanced Therapies Unit, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.
    (12) Urology Department, University Hospital '12 de Octubre', Madrid, Spain.
    (13) Medical Oncology Department, University Hospital '12 de Octubre', Madrid, Spain.
    (14) Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain.
    (15) Hemato-oncology Program, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, Pamplona, Spain.
    (16) Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain.
    (17) Hemato-oncology Program, Centro de Investigación Médica Aplicada, IDISNA, Universidad de Navarra, Pamplona, Spain.
    (18) Hematology and Cell Therapy Department, Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain.
    (19) Molecular Oncology Unit CIEMAT, Madrid, Spain.
    (20) Centro de Investigación Biomédica en Red Cáncer, Madrid, Spain.
    (21) Institute of Biomedical Research, University Hospital '12 de Octubre', Madrid, Spain.

    Nature Medicine 03 JULY 2019

  • Increasing Interest of Mass Communication Media and the General Public in the Distribution of Tweets About Mental Disorders

    Alvarez-Mon MA (1), Asunsolo Del Barco A (2,3), Lahera G (3,4,5), Quintero J (6), Ferre F (7), Pereira-Sanchez V (1), Ortuño F (1), Alvarez-Mon M (3,4).

    (1) Department of Psychiatry, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (2) Department of Surgery, Medical and Social Sciences, University of Alcala, Madrid, Spain.
    (3) Instituto Ramón y Cajal de Investigaciones Sanitarias, Madrid, Spain.
    (4) Department of Medicine and Medical Specialities, Hospital Universitario Príncipe de Asturias, University of Alcala, Madrid, Spain.
    (5) Center for Biomedical Research in the Mental Health Network, Madrid, Spain.
    (6) Department of Psychiatry, Hospital Universitario Infanta Leonor, Complutense University, Madrid, Spain.
    (7) Department of Psychiatry, Hospital Universitario Gregorio Marañón, Complutense University, Madrid, Spain.

    Journal of Medical Internet Research 28 MAY 2019

  • Is it worth to perform preoperative MRI for breast cancer after mammography, tomosynthesis and ultrasound?

    González-Huebra I (1), Elizalde A (2), García-Baizán A (3), Calvo M (4), Ezponda A (5), Martínez-Regueira F (6), Pina L (7).

    (1) Department of Radiology, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.
    (2) Department of Radiology, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.
    (3) Department of Radiology, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.
    (4) Department of Radiology, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.
    (5) Department of Radiology, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.
    (6) Department of General Surgery, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.
    (7) Department of Radiology, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.

    Magnetic Resonance Imaging 01 APRIL 2019

  • Identification of mutations associated with acquired resistance to sunitinib in renal cell-cancer

    Elgendy M (1,2), Fusco JP (3,4), Segura V (5), Lozano MD (4,6,7), Minucci S (1,8), Echeveste JI (4,6), Gurpide A (3,4), Andueza M (3,4), Melero I (4,7,9), Sanmamed MF (3,4), Ruiz MR (3,4), Calvo A (4,10), Pascual JI (4,11), Velis JM (4,11), Miñana B (4,11), Valle RD (4,12), Pio R (4,7,13), Agorreta J (4,7,13), Abengozar M (4,6), Colecchia M (14), Brich S (14), Renne SL (14), Guruceaga E (5), Patiño-García A (4,13,15), Perez-Gracia JL (3,4,7).

    (1) Department of Experimental Oncology, European Institute of Oncology (IEO), Milan, Italy.
    (2) Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria.
    (3) Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain.
    (4) Health Research Institute of Navarra (IDISNA), Pamplona, Spain.
    (5) IDISNA and Bioinformatics Unit, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Navarra, Spain.
    (6) Pathology Department, Clinica Universidad de Navarra, Pamplona, Spain.
    (7) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC).
    (8) Department of Biosciences, University of Milan, Milan, Italy.
    (9) Department of Immunology, Center for Applied Medical Research (CIMA), Pamplona, Spain.
    (10) Department of Histology and Pathology, School of Medicine, University of Navarra, Pamplona, Navarra, Spain.
    (11) Department of Urology, Clinica Universidad de Navarra, Pamplona and Madrid, Spain.
    (12) Department of Neurosurgery, University Clinic of Navarra, Pamplona, Spain.
    (13) Program in Solid Tumors. Center for Applied Medical Research (CIMA), Pamplona, Spain.
    (14) Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
    (15) Department of Pediatrics and Clinical Genetics, Clinica Universidad de Navarra, Pamplona, Spain.

    International Journal of Cancer 08 MARCH 2019

  • iNOS Gene Ablation Prevents Liver Fibrosis in Leptin-Deficient ob/ob Mice

    Becerril S (1,2,3), Rodríguez A (4,5,6), Catalán V (7,8,9), Ramírez B (10,11,12), Unamuno X (13,14,15), Gómez-Ambrosi J (16,17,18), Frühbeck G (19,20,21,22).

    (1) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Spain.
    (3) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
    (4) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
    (5) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Spain.
    (6) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
    (7) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
    (8) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Spain.
    (9) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
    (10) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
    (11) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Spain.
    (12) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
    (13) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
    (14) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Spain..
    (15) Medical Engineering Laboratory, University of Navarra, Pamplona, Spain. 
    (16) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain
    (17) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Spain.
    (18) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
    (19) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain
    (20) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Spain..
    (21) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. 
    (22) Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, Pamplona, Spain.

    Genes 27 FEBRUARY 2019

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra